SCM
CLDX icon

Sigma Capital Management’s Celldex Therapeutics CLDX Stock Holding History

Sigma Capital Management’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-1,000
Closed -$265K – 22
2014
Q1 		$265K Sell
1,000
-3,371
-77% -$1.29M 0.01% 162
2013
Q4 		$1.59M Sell
4,371
-14,296
-77% -$5.51M 0.09% 135
2013
Q3 		$9.92M Sell
18,667
-7,000
-27% -$2.4M 0.41% 68
2013
Q2 		$6.01M Buy
+25,667
New +$5.05M 0.28% 96

Other funds holding CLDX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CWAM
Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Sigma Capital Management's CLDX Position: Q2 2014 in Review

Sigma Capital Management sold out of Celldex Therapeutics (CLDX) in Q2 2014, closing a stake of 1,000 shares — an estimated $265K sold.

Sigma Capital Management first reported a position in CLDX in Q2 2013 and held it in 4 quarters. The position peaked at $9.92M in Q3 2013. 135 funds tracked by Wall St. Rank hold CLDX as of Q2 2014.

  • Sigma Capital Management reported no remaining Celldex Therapeutics position as of Q2 2014 after selling out during the quarter.
  • Sigma Capital Management sold 1,000 Celldex Therapeutics shares in Q2 2014, an estimated $265K.
  • Sigma Capital Management first reported a position in Celldex Therapeutics in Q2 2013 and held it in 4 quarters.
  • Sigma Capital Management's Celldex Therapeutics position peaked at $9.92M in Q3 2013.
  • 135 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q2 2014.

Based on Sigma Capital Management's 13F filing for Q2 2014.